Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Handout presentations in PDF for illustrating lectures
Accessed May 2014
Dziva Chikwari et al. Implementation Science (2018) 13:70 https://doi.org/10.1186/s13012-018-0762-5
Five years after a global commitment to Fast-Track the HIV response and end AIDS by 2030, the world is off track. A promise to build on the momentum created in the first decade of the twenty-first century by front-loading investment and accelerating HIV service provision has been fulfilled by too fe...w countries.
more
This handbook aims to help labour inspectors deal with the issue of HIV/AIDS.
It establishes the links between the key principles and core responsibilities of labour inspectorates and the management of HIV/ AIDS at the workplace.
It includes training activities and practical tools to help inspecto...rs integrate HIV/AIDS in their work.
more
AIDS Research and Therapy 2015, 12:12 (24 April 2015)
HIV Treatment
Policy Brief
July 2017
Journal of Social Aspects of HIV/AIDS VOL. 14 NO. 1 2017
SAHARA J. 2017; 14(1): 77–84.
Published online 2017 Sep 21. doi: 10.1080/17290376.2017.1374878
PMCID: PMC5639614
PMID: 28934916
The overall goal of the programme, to reduce the malaria morbidity and mortality by 75% (using 2012 as baseline) by the year 2020, continued to be pursued in 2014. The following areas were identified as some of the priorities for the year: Malaria Case Management under which we have Malaria in Pregn...ancy (MIP), Home Based Care and Diagnostics.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
Based on research by a team of Nepalese and international experts, this report carries an analysis of the five key elements in the sector - land, basic services, housing finance, building materials and construction technologies, and labour. It gives an assessment
of how these components are governe...d by policy, institutional and legal frameworks, and how they are linked with one another and other urban policies.
more
Cardiovascular disease, heart disease, and coronary heart disease may sound similar but they are not one in the same. This fact sheet will help you understand how these conditions differ.
Handout presentations in PDF for illustrating lectures
Accessed May 2014
This Commission report aims to contribute to a new era of multilateral cooperation based on strong UN institutions to reduce the dangers of COVID-19, forestall the next pandemic, and enable the world to achieve the agreed goals of sustainable development, human rights, and peace that governments are... committed to pursue as members of the UN. We address this Commission report to the UN member states, the UN agencies and multilateral institutions, and multilateral processes such as the G20 and the G7.
more
Practice paper in Brief 24
Containment strategies for Ebola rupture fundamental features of social, political and religious life. Control efforts that involve local people and appreciate their perspectives, social structures and institutions are therefore vital